Cargando…
Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies
In recent years, the prevalence of metabolic-associated fatty liver disease (MAFLD) has reached pandemic proportions as a leading cause of liver fibrosis worldwide. However, the stage of liver fibrosis is associated with an increased risk of severe liver-related and cardiovascular events and is the...
Autores principales: | Dong, Qingfu, Bao, Haolin, Wang, Jiangang, Shi, Wujiang, Zou, Xinlei, Sheng, Jialin, Gao, Jianjun, Guan, Canghai, Xia, Haoming, Li, Jinglin, Kang, Pengcheng, Xu, Yi, Cui, Yunfu, Zhong, Xiangyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157161/ https://www.ncbi.nlm.nih.gov/pubmed/37153080 http://dx.doi.org/10.3389/fmed.2023.1120621 |
Ejemplares similares
-
Tertiary lymphoid structures in pancreatic cancer: a new target for immunotherapy
por: Zou, Xinlei, et al.
Publicado: (2023) -
AR-induced ZEB1-AS1 represents poor prognosis in cholangiocarcinoma and facilitates tumor stemness, proliferation and invasion through mediating miR-133b/HOXB8
por: Jiang, Xingming, et al.
Publicado: (2020) -
Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
por: Qu, Weiyi, et al.
Publicado: (2021) -
MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis
por: Huang, Jiaofeng, et al.
Publicado: (2021) -
Editorial: Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
por: Sandoval-Rodriguez, Ana, et al.
Publicado: (2022)